Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) is causally associated with several malignant tumors: Kaposi’s sarcoma (KS), multicentric Castleman’s disease (MCD), and primary effusion lymphoma (PEL). KS remains the most common AIDS-related malignancy since the AIDS epidemic and thus has been extensively studied. KS is characterized as an angioproliferative disease with massive immune cell infiltration at the early stage. High levels of proinflammatory cytokines and growth factors are found in KS lesions, and their involvement in the survival and growth of tumor cells has been well characterized. However, little is known about the role of the inflammatory microenvironment in the regulation of KSHV gene expression and/or viral replication. In the present study, we demonstrated that IFN-γ and TNF-α profoundly inhibited KSHV progeny production in primary human lymphatic endothelial cells (LECs) as well as induced KSHV-producer cells (iSLK.219) with doxycycline. Of note, IFN-γ inhibited overall KSHV gene expression, while the effects of TNF-α were confined to a selected set of genes, which were also downregulated by IFN-γ. The addition of IFN-γ up to 36 hr after induction of viral lytic replication was effective in terms of the inhibition of infectious virion production, suggesting that its inhibitory effect is exerted at the early stages of KSHV life cycle. We believe these data have potentially important implications for rationalizing a therapeutic agent to treat KSHV-induced tumors in which lytic replication plays a critical role in their pathogenesis: KS and MCD.
Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV) belongs to the human herpesvirus γ-subfamily along with Epstein-Barr virus (EBV). The primary infection targets in vivo include endothelial and B cells, causing various malignancies, especially in immunodeficient hosts: Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL), and a subset of multicentric Castleman’s disease (MCD). Among KSHV-infected disorders, KS has been the main focus of study in the KSHV field, as it is the most common AIDS-related malignancy, and in vitro infection models are available. Although it bears the word sarcoma in its name, KS may be a misnomer1, as it is clearly distinct from classical sarcomas in many ways: (1) KS lesions contain many different cell types (2–4 and reviewed in5,6), unlike traditional sarcomas, which mainly consist of a single cell type; (2) immune infiltrates as well as the tumor elements (so-called “spindle cells”) in the lesions produce a wide variety of proinflammatory and angiogenic products (7 and reviewed in8); (3) the growth of spindle cells in vitro depends generally on the presence of exogenous growth factors such as cytokines and growth factors9,10. Therefore, it has been suggested that KS has features of a reactive hyperplasia or inflammatory angioproliferative process, which is a clear distinction from classical sarcomas. In line with this notion, an array of mRNAs encoding cytokines and growth factors are detected in KS lesions, including TNF-α, TNF-β, IFN-γ, IL-1β, IL-6, platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) (11–13 and reviewed in9). In addition, KS spindle cells generate a variety of cytokines and growth factors upon in vitro explant culture, such as vascular endothelial growth factor (VEGF), bFGF, IL-8, IL-1β and IL-614–18. Of note, in vitro growth of KS spindle cells entails the use of conditioned media from activated lymphocytes19,20, which contain high levels of IL-6, TNFs, IFN- γ, IL-1β, and oncostatin M (OSM). Thus, one may envision that these proinflammatory cytokines present in the lesions play a central role in the KS pathogenesis. Indeed, IL-1β and PDGF were identified as major mitogens for the spindle cells in vitro12,21. VEGF, upregulated by several KSHV gene products, is a prominent angiogenic factor, so it is likely responsible for neovascularity and edema in affected tissues22,23. bFGF is highly expressed in KS lesions and is known to promote spindle cell growth in an autocrine and paracrine pattern in vitro7. Furthermore, cytokines produced from activated T cells seem to be responsible for phenotypic and functional changes in endothelial cells relevant to the pathogenesis of KS24. Therefore, it is clear that many of these proinflammatory and angiogenic factors are involved in the initiation and growth of KS tumors.
What has remained unclear is whether inflammatory signals can modulate KSHV gene expression and/or replication25. In the present study, to shed light on the potential roles of proinflammatory cytokines and growth factors on KSHV lytic replication, we first examined the identities of proinflammatory and growth factors differentially expressed in the conditioned medium (CM) from the human tonsillar explant culture. Among them, IFN-γ and TNF-α had a profound inhibitory effect on infectious virion production in primary human LECs as well as a KSHV-producer cell line (iSLK.219). Interestingly, inhibitory mechanisms of IFN-γ and TNF-α seem to be distinct: IFN-γ inhibits overall viral transcription, while TNF-α does not. Furthermore, IFN-γ seems to act early in the virus life cycle because the addition of IFN-γ up to 36 hr post-induction of viral lytic replication is effective enough to reduce the number of infectious viruses in the culture supernatant. Notably, both IFN-γ and TNF-α inhibit viral replication in LECs but not in human umbilical vein endothelial cells (HUVECs) or hTERT-immortalized microvascular endothelial cells (TIME). Taken together, our data strongly suggest that proinflammatory cytokines (IFN-γ and TNF-α) can modulate KSHV replication in a cell type-specific manner. Further delineation of the underlying molecular mechanisms will provide a rationale to develop effective anti-viral therapeutics against KSHV-induced endothelial pathology.
Results
IFN-γ and TNF-α impair KSHV progeny production
The roles of proinflammatory cytokines found in KS lesions have mostly been studied in primary effusion lymphoma (PEL)-derived cells such as body cavity-based cells (BCBL-1), BC-1, or BC-3. A few cytokines and chemokines induce the expression of selected sets of lytic genes in treated PEL cell lines. However, those immune-modulatory cytokines/chemokines/growth factors are found in the lesion, and infiltrating mononuclear cells are not infected. Therefore, it is possible that primary targets of proinflammatory cytokines are endothelial cells and endothelial cell-derived spindle cells. Few studies have analyzed the effects of those cytokines/chemokines on the primary target of KSHV infection: endothelial cells. To study the roles of cytokines/chemokines on KSHV lytic replication, we first sought using 64-plex ELISA the identities of cytokines, chemokines, or growth factors in the culture supernatants of tonsillar cells (see Materials and Methods). Briefly, 1 × 106 KSHV-infected or naïve B cells were co-cultured for two days with 1 × 106 naïve B or T cells with or without phytohemagglutinin (PHA) stimulation. Culture supernatants were harvested and analyzed for levels of cytokines/chemokines/growth factors. A selected set of them are summarized in Table 1. Of note, expression levels of one of the two chemokines (IP-10), three cytokines (IFN-γ, TNF-α, TNF-β), and one growth factor (platelet-derived growth factor A homo-dimer, PDGF-AA) were ca. 50% higher in the culture supernatants from the co-culture of infected B cells and PHA-stimulated T cells than those from PHA-stimulated T cell alone, implying KSHV infection in tonsillar B cells may modulate immune-regulatory molecules. To examine effects of these cytokines/chemokines/growth factors on KSHV replication in iSLK.219 cells, a Dox-inducible KSHV-harboring SLK cell line26,27, cells were induced with Dox (0.2 μg/ml) and treated with each indicated molecule at the time of induction (Fig. 1). To analyze the different effects of PDGF isoforms, various homo- or hetero-dimers of PDGF were investigated as well. As vascular endothelial growth factor (VEGF) is expressed at high levels in KSHV lesions, it was included in this study as well, although its level in the conditioned medium was low (data not shown). At d 3 post-induction, infectious virus titers in the culture supernatants were determined (Fig. 1A). Notably, IFN-γ and TNF-α inhibited infectious virus production by over 90%, while TNF-β and IP-10 displayed moderate (50~60%) inhibition on KSHV lytic reactivation. Interestingly, KSHV genome replication was severely impaired by IFN-γ at both high and low concentrations (Fig. 1B). In addition, the differences in inhibitory activity between the two doses of IFN-γ were statistically significant (P < 0.01 at 96 and 120 hr post-treatment). The inhibitory effect of TNF-α on viral DNA synthesis was initially apparent. However, it largely disappeared at later stages of viral replication (Fig. 1C). As IFN-γ and TNF-α demonstrated a strong inhibitory activity on infectious virus production in iSLK.219 cells, we hypothesized that expression of lytic genes may be negatively affected by the treatment of those cytokines. As rKSHV.219 harbors a RFP expression cassette, expression of which is driven by a KSHV lytic gene promoter, levels of RFP expression in the presence/absence of IFN-γ or TNF-α at varying concentrations were examined (Fig. 2). Without induction with Dox, few cells were positive for RFP. At d2 post-induction, ca. 12% cells expressed RFP, indicating those cells are lytically activated. Of note, when iSLK.219 cells were treated with Dox and IFN-γ (5000 units/ml), RFP expression was decreased by 86% compared to that of the Dox alone control, and even at the lowest IFN-γ concentration (8 units/ml), RFP expression was reduced by 71%. Interestingly, TNF-α treatment did not show any reduction of RFP expression, implying that the mechanisms of those two cytokines are likely to be different.
Table 1.
Co-culture | IP-10 | RANTES | IFN-γ | TNF-α | TNF-β | PDGF-AA | |
---|---|---|---|---|---|---|---|
Infected | Uninfected | ||||||
(unit: ng/ml§) | |||||||
B | none | ND | 0.1 | 0.4 | ND | 0.3 | 0.1 |
B | B | ND | 2.0 | 2.9 | 0.2 | 1.0 | 0.1 |
none | T w/o PHA* | 3.7 | 54.1 | 2.4 | 8.4 | 3.3 | 1.7 |
none | T w/PHA# | 3.9 | 189.5 | 7.1 | 22.5 | 5.3 | 4.1 |
B | T w/o PHA | 4.8 | 48.2 | 2.6 | 6.5 | 1.5 | 0.4 |
B | T w/PHA | 6.7 | 190.5 | 12.8 | 38.8 | 7.3 | 6.9 |
The mean of duplicated samples is shown.
*T cells not stimulated with phytohaemagglutinin (PHA);
#T cells stimulated with PHA for 6 hr prior to co-culture with B cells; ND, not detected.
§Specific activity of each cytokine was not measured. For comparison, specific activities of recombinant proteins utilized in this study are provided. RANTES: 2 × 105 units/mg; IP-10, IFN-γ, TNFs, PDGF isotypes: 2 × 107 units/mg.
IFN-γ and TNF-α inhibit infectious KSHV virion production in primary human LECs
As IFN-γ concentration was determined to be 250 units/ml in the conditioned medium of the co-culture of infected B and stimulated T cells (Table 1), we hypothesized that T cell-derived IFN-γ may have a profound effect on KSHV replication in endothelial cells. As SLK cells turned out to be an epithelial cell line28, confirmation of IFN-γ-mediated inhibition of KSHV replication in primary endothelial cells is of paramount importance. LEC’s have been suggested to be the most physiologically relevant target in vivo29. Therefore, three different primary human cells were employed for comparisons: LECs, HUVECs, and human telomerase reverse transcriptase (hTERT)-immortalized microvascular endothelial cells (TIME). Primary endothelial cells were infected with rKSHV.219 at MOI = 10, and unbound viruses were extensively washed off before the addition of IFN-γ (Fig. 3A) and TNF-α (Fig. 3B) in the culture at varying concentrations. Infectious virus titers in the culture supernatant were determined at d 2 (top panels) or d 3 post-infection (bottom panels). Notably, only LECs, a likely infection target in vivo29,30, demonstrated IFN-γ-mediated inhibition, while HUVEC and TIME did not, suggesting the biological and physiological importance of IFN-γ in vivo.
The different responses of primary endothelial cells to IFN-γ and TNF-α are not related to the expression levels of cognate cytokine receptors on the cell surface
To investigate the basis of the different outcomes of cytokine treatment on different cell types, the expression of the ligand-binding polypeptide chain of their cognate receptors on the cell surface was assessed by flow cytometry using specific antibodies (Fig. 4). Interestingly, levels of the cytokine receptors (IFN-γ receptor 1 (IFNGR1 (CD119)) and TNF-α receptor α chain (TNFRα (CD120a)) were comparable among all the cell types examined: LECs, HUVECs, TIME, and SLK cells. These data suggest that the differences in the capacity and/or scope of intracellular signaling upon ligand binding on the surface are likely responsible for the different outcomes of cytokine treatment.
IFN-γ inhibits early stages of KSHV lytic replication
To investigate which stages of viral replication are affected by IFN-γ, iSLK.219 cells were induced with Dox (0.2 μg/ml), and IFN-γ (0, 20, 200 units/ml) was added into the culture at varying time points. At 72 hr post-induction, culture supernatants were collected for the evaluation of infectious titer (Fig. 5). When IFN-γ was administered up to 36 hr post-induction, KSHV progeny production was significantly inhibited in a dose-dependent manner. As it takes usually 48 hr before any viruses are detectable in the culture supernatant of iSLK.219 cells upon induction27, it is reasonable to conclude that IFN-γ inhibits early stages (immediate-early or delayed-early) of KSHV lytic replication.
The effect of IFN-γ treatment on viral transcriptome and protein expression
To analyze how IFN-γ and TNF-α affect viral gene expression, SLK, iSLK, and iSLK.219 cells were left uninduced or induced with Dox (0.2 µg/ml), and at the same time, IFN-γ or TNF-α was added in the culture at the indicated concentration (0, 20, or 200 units/ml). At d 2 post-induction, cell lysates were prepared for Western blot analysis. Various viral proteins were blotted using specific antibodies: LANA (latent), RTA and ORF45 (immediate-early), ORF59, vIL-6 (K2), KbZIP (K8), and ORF57 (delayed-early). Of note, IFN-γ inhibited viral gene expression in a dose-responsive manner, especially RTA, ORF59, and K8, all of which play important roles in viral DNA synthesis (Fig. 6). Apparently, TNF-α had little, if any, effect on viral gene expression, which is consistent with normal RFP expression driven by RTA (Fig. 2). To investigate if IFN-γ-mediated inhibition of viral protein expression is at the transcriptional level, Dox-induced iSLK.219 cells were treated with each cytokine at 36 hr post-induction. The time point was selected based on the data in Fig. 5, because infectious virus particle production was sensitive to cytokine treatment up to that time point. At 4 hr post-treatment, total RNA was extracted for microarray analysis of the viral transcriptome (Fig. 7A). Notably, IFN-γ inhibited overall viral gene transcription in a dose-dependent manner while TNF-α-mediated inhibition was evident only in a limited number of viral genes. Moreover, several genes were regulated by both IFN-γ and TNF-α, most of them immediate-early or delayed-early genes (RTA; lytic switch protein, ORF6; DNA-binding protein, ORF9; DNA polymerase, ORF56; DNA replication protein, K5 & K7; regulators of cellular proteins). This is in line with the notion that IFN-γ regulates early stages of viral replication (Fig. 5). Interestingly, among genes that were affected by both IFN-γ and TNF-α were ORF K13 (vFLIP) and ORF 72 (vCyclin D). Currently, studies are underway to analyze the biological significance of cytokine-mediated reduction of viral gene expression in the course of KSHV lytic replication. The identities and levels of significantly affected genes are summarized in Fig. 7B31,32.
Discussion
KS is the most common AIDS-related malignancy since the AIDS epidemic in the early 1980’s. It is characterized by extensive angiogenesis, spindle cell proliferation, and massive immune cell infiltration. High levels of proinflammatory cytokines are detected in KS lesions, and their roles in the KSHV-induced pathologies have been postulated to help in the proliferation of tumor elements and recruitment of naïve cells for viral spreading and thus the initiation and/or development of KS lesions (reviewed in6,8). However, their involvement in the regulation of viral replication remains undefined. It is worth noting that Parravicini et al.33 analyzed expression of 4 KSHV proteins (LANA, vIRF1, vIL-6 and PF-8) by immuno-histochemistry, showing that KSHV protein expression is somewhat restricted in vivo, while viral lytic proteins are readily detected in KSHV-infected cell lines in vitro. On the other hand, some other studies detected expression of more numbers of lytic gene transcripts in at least a subset of AIDS-KS patients with or without anti-retroviral therapies34–36, hinting at a tug of war for viral gene expression between viruses and the host. These data suggest that differential protein expression in vivo vs in vitro may be related to immune restriction of viral replication. To shed light on the roles of proinflammatory cytokines on KSHV replication, we employed human lymphoid aggregate culture (HLAC) prepared from tonsils based on several reasons: (1) KSHV titer is highest in the saliva among all the human body fluids37, and some epidemiological studies implicate horizontal transmission as the primary mode of infection by viruses shed in the saliva38–41; (2) tonsils are localized in the oral cavity and a rich source of lymphocytes, where activated T cells seem to suppress spontaneous lytic replication in infected B cells, as suggested by in vitro studies employing HLAC42,43; (3) infiltrating T cells in KS lesions produce an array of cytokines, which support the survival and growth of spindle cells, the tumor element of the lesions1,9,10. Thus, we hypothesized that conditioned media from the HLAC culture would also affect the course of KSHV infection. Based on 64-plex ELISA on the conditioned medium (Table 1), a dozen differentially expressed proinflammatory cytokines/chemokines/growth factors were selected and investigated for their ability to regulate KSHV replication. The list of proinflammatory cytokines (Table 1) is largely in line with previous studies (24,44–48 and reviewed in9). Interestingly, strong inhibition of viral progeny production was observed in induced iSLK.219 and infected LECs treated with IFN-γ- or TNF-α (Figs 1, 3 and 4). Both IFN-γ- and TNF-α are found at high levels in KS lesions (24,44,49 and reviewed in1). To our knowledge, this is the first report to demonstrate the inhibitory effects of these cytokines on infectious virion production in LECs, the most physiologically relevant cell type for KS of endothelial origin.
One may envision that IFN-γ-mediated antagonism of KSHV lytic replication may seem contrary to the results of previous studies using KSHV-harboring B cell lymphoma cell lines. In fact, several groups have shown that IFN-γ promotes viral lytic gene expression in BCBL-1 or BC-1 cells50,51. These discrepancies may be simply explained by cell-type-specific differences in response to proinflammatory cytokines. However, those studies analyzed only selected sets of viral lytic genes, such as RTA, ORF59, or K8.1 at the transcriptional49–51 or translational49,50 level, and the consequences of the increases in viral mRNA levels were not evaluated in terms of viral progeny production. Of note, Pozharskaya et al.52 showed that the treatment of IFN-γ (200 units/ml) induced expression of antiviral proteins in BCBL-1 cells, such as double-stranded RNA-activated protein kinase (PKR), 2′5′-oligoadenylate synthetase (2′5′-OAS) and interferon regulatory factor 1 (IRF1), expression of which subsequently led to 60% reduction in the production of infectious virus induced by TPA although IFN-γ indeed stimulated a minor increase in the expression of selected viral lytic genes in the IFN-γ-treated BCBL-1 cells. More detailed and careful studies are warranted to define the roles of proinflammatory cytokines on KSHV replication in KSHV-harboring B cell lymphoma cells. In addition, it remains to be examined if induction of lytic replication by IFN-γ actually takes place in patients with B cell lymphomas, leading to production of infectious viruses in vivo. Furthermore, as only a small portion of PEL cell lines in culture are lytically activated in vitro, the biological significance of limited lytic replication in B cell lymphomas, even if happening in vivo, is questionable. Moreover, PEL cases are mostly monoclonal tumors and thus may not depend on the expression of lytic genes for tumor growth1,8,9. However, we cannot formally exclude the possibilities that spontaneous lytic replication occurs in vivo in patients with PEL tumors and that lytic gene products promote angiogenesis and tumor growth as some lytic gene products are known to function to that end22,53.
The lack of an animal model to analyze KSHV pathogenicity makes it difficult to elucidate the roles of proinflammatory cytokines in the context of viral infection in vivo. The role of IFN-γ in the control of viral replication in vivo has been studied using a mouse herpesvirus. In murine gammaherpesvirus 68 (MHV68) infections, a close cousin of KSHV, IFN-γ plays a critical role in the regulation of a chronic gammaherpesvirus infection54,55 and in the inhibition of reactivation from latency depending on cell types analyzed56,57: macrophages were sensitive to IFN-γ-medicated inhibition, but B cells were not. Taken together, these data suggest that IFN-γ seems to regulate gammaherpesvirus replication in a cell type-specific manner.
It is interesting to note that the mechanisms of action of IFN-γ and TNF-α may diverge in terms of RFP expression (Fig. 2), which is driven by the PAN promoter harboring the RTA-responsive element, and in viral gene expression at the transcriptional (Figs 6 and 7) and translational (Fig. 6) levels. IFN-γ treatment led to a sharp decrease in RFP expression, while TNF-α treatment did not (Fig. 2), in spite of its comparable inhibitory activities on infectious KSHV progeny production in transformed (Fig. 1) and primary endothelial cells (Fig. 3). Because extracellular levels of ligand-binding subunits of cytokine receptors were largely comparable on those cells (Fig. 4), it would be reasonable to postulate that differences in intracellular signaling pathways activated by IFN-γ or TNF-α ligation on the cognate receptor of various cell types may lead to differential outcomes of viral gene expression, viral DNA synthesis, capsid assembly, viral exit, or combinations thereof. Hints of their differential mechanisms came from viral protein expression (Fig. 6) and transcriptome analysis (Fig. 7). IFN-γ inhibited important KSHV lytic genes at both the transcriptional and translational levels, such as RTA, ORF45, ORF59, vIL-6 and K8, while TNF-α had little effect on them. Its underlying molecular mechanisms are now being investigated. Notably, the addition of IFN-γ up to 36 hr after induction of lytic replication effectively reduced infectious virion production (Fig. 5) in the culture supernatant, suggesting that IFN-γ inhibits early stages of KSHV replication. In line with this notion, the list of genes downregulated by IFN-γ includes the immediate-early RTA (lytic switch) and the delayed-early ORF6 (single-stranded DNA-binding protein, homologue of EBV Balf2 and HSV-1 ICP8), ORF9 (DNA polymerase), ORF56 (primase), and K8 (KbZIP), all of which are associated with Ori-Lyt-dependent DNA replication (Figs 6 and 7). In a previous report58, IFN-γ-mediated inhibition of RTA gene expression is substantiated by reduced RTA promoter activity in transformed dermal microvascular endothelial cells (tDMVEC), suggesting transcriptional regulation of RTA by the cytokine. Furthermore, fold increase of the KSHV genome copy number (Fig. 1B), an indication of initiation of the late stage of KSHV replication, became statistically significant by 48 hr post-induction with Dox: untreated (1 ± 0.02) vs Dox (2.01 ± 0.01) at 48 hr; p < 0.01. Taken together, it is reasonable to conclude that IFN-γ inhibits KSHV lytic replication and viral progeny production by interfering with early stages of the virus life cycle, including but not limited to, viral DNA synthesis.
Interestingly, the inhibitory mechanisms of TNF-α seem to be very different from those of IFN-γ, as viral gene expression was in general unaffected by TNF-α treatment at the transcriptional and translational levels, except for a subset of genes (Figs 6 and 7) that were downregulated at the transcriptional level: ORF6, ORF9, ORF30, ORF31, ORF56, ORF K5, ORF71 (vFLIP), and ORF72 (vCyclin). We could not analyze their protein levels due to the lack of good specific antibodies. A few plausible explanations for the relative lack of effect of TNF-α include; (1) TNF-α may modulate viral assembly or exit without much changing the viral transcriptome (Fig. 7) or viral DNA synthesis (Fig. 1C). Some previous studies support this notion as TNF-α did not affect viral gene expression in BCBL-1 cells51. (2) TNF-α may downregulate the translation of select viral genes without affecting transcription in general, and some of those affected genes may be indispensable for KSHV lytic replication. Indeed, ORF6, ORF9, and ORF56, which were downregulated by TNF-α, participate in the formation of the replication complex on the lytic origins. (3) TNF-α may activate intracellular host signaling molecules that inhibit various stages of the viral life cycle. For example, TNF-α activates NF-κB signaling, which counteracts KSHV lytic replication and thus promotes viral latency59–61. Comparable levels of cognate cytokine receptors on the surface of transformed and primary endothelial cells as well lend support to the possible roles of intracellular signaling molecules activated by TNF-α (Fig. 4). In reality, to some extent, all of the above mechanisms may contribute to the inhibition of viral progeny production by TNF-α. Mechanistic studies are currently underway to define the underlying mechanisms of inhibitory activities of TNF-α on KSHV replication.
Taken together, our data demonstrate that IFN-γ and TNF-α, found at high levels in KS lesions, exert profound inhibitory effects on infectious KSHV virion production. These data suggest that proinflammatory cytokines not only modulate spindle cell proliferation and angiogenesis but also regulate viral replication. Considering the highly lytic nature of in vitro KSHV infection in LECs (Fig. 3 and unpublished observations)29, it is tempting to postulate by extrapolation that viral infection in endothelial cells in vivo may be rendered latent by the inflammatory microenvironment in KS lesions. This is in line with previous histological, virological, and immunological findings that most infected cells in KS lesions are tightly latent33,62. Therefore, it would be interesting to determine if these cytokines play a role in pushing spindle cells into latency in vivo, as seen in primary endothelial cells in vitro. Last but not least, our data provide a rationale to potentiate IFN-γ and TNF-α signaling pathways in infected cells of patients with KSHV-induced tumors, where lytic replication plays an important role in the pathogenesis: KS and MCD. Caution is warranted, though, as pleiotropic cytokines such as IFN-γ and TNF-α affect many different cell types and direct systemic or local administration of them may have unwanted aftermaths63–65.
Materials and Methods
Cells and reagents
QBI293A cells (Q-Biogene) were used to titrate rKSHV.219 stocks prepared from stable iSLK.219 cells harboring the recombinant virus, which was described before27,66. Briefly, parental SLK cells were implanted with a Dox-inducible RTA-expressing system (pRetroX-Tet-On Advanced, Clontech) to generate iSLK cells. rKSHV.219 viruses were infected into iSLK cells, and the resulting cells were selected by puromycin to generate iSLK.219 cells. Primary human LECs, blood endothelial cells (BECs), and HUVECs were purchased from Lonza. Human TERT-immortalized dermal microvascular endothelial cells (TIME) were described elsewhere67. LECs, BECs, and TIME cells were cultured in EBM-2 media supplemented with the EGM-2MV BulletKit while HUVEC media were supplemented with the EGM BulletKit. Human lymphoid aggregate culture (HLAC) was prepared and used for this study as described previously42,68. SLK cell lines were maintained in DMEM containing 10% fetal bovine serum with supplements as described before26 (1% penicillin-streptomycin (Life Technologies) and antibiotics (250 μg/ml G418, 400 μg/ml hygromycin, 10 μg/ml puromycin, 1 μg/ml blasticidin (Invivogen))). Antibiotic-free medium was used when cells were induced to lytic replication with doxycycline (Dox, 0.2 μg/ml). All cytokines, chemokines, and growth factors were purchased from Peprotech except platelet-derived growth factor CC isoform (PDGF-CC, R&D Systems) and resuscitated according to the instructions. Anti-human CD119 (IFN-γRα chain, GIR-94) and anti-human CD120a (TNF-αRα chain) antibodies were purchased from Biolegend.
Antibodies specific to viral proteins were purchased from various vendors; K8 from Santa Cruz, ORF45 and ORF57 from Abcam, β-actin from Sigma-Aldrich, ORF59 from Advanced Biotechnologies. LANA and RTA antisera were custom-made in rabbits.
Detection of cytokines, chemokines, and growth factors in the culture supernatants from tonsillar cell co-cultures
One hundred microliters of duplicated culture supernatants were used for 64-plex ELISA using the human cytokine array service (Cat # HD64) from Eve Technologies (Alberta, Canada). Raw assay results provided by the company were sorted for molecules over the detection limit and differential expression levels were summarized in Table 1.
Virus preparation, infection and titration
Virus stocks were prepared from induced iSLK.219 cells as described elsewhere27,42. Briefly, induced culture medium was cleared and pelleted by a series of centrifugations, and virus pellets were resuspended in an appropriate cell culture medium. Infectious virus titers of virus stocks and samples were determined in QBI293A cells as previously described43. In brief, QBI293A cells were infected with rKSHV.219-containing samples by spinoculation and were cultured for 2 days before subjected to flow cytometry. Virus titers were determined by using the Poisson distribution formula: virus titer = −N × ln (1 − P), where N and P denotes the total number of cells and the proportion of GFP-positive cells in a given well, respectively. Virus stocks were diluted and infected into primary human endothelial cells by spinoculation43 at the indicated multiplicity of infection (MOI). Dox-induced iSLK.219 cells or infected human primary endothelial cells were treated with various cytokines, chemokines, or growth factors for the indicated time periods before culture supernatants were collected for virus titration.
Quantitation of the relative genomic copy number of rKSHV.219 in iSLK.219 cells
Genomic DNA was extracted from cells using DNeasy Blood & Tissue Kit (Qiagen, USA). The relative copy number of KSHV genomic DNA in total DNA was assessed by CFX Connect Real-Time PCR Detection System (Biorad, USA) using the AccuPower 2X GreenStar qPCR Master Mix with primers specific for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control and KSHV-encoded latency-associated nuclear antigen (LANA). GAPDH forward: 5′-TCATCCAAGCGTGTAAGGGT-3′; GAPDH reverse: 5′-GGACTGAGATTGGCCCGAT-3′; LANA forward: 5′-AAACAGAAACGGCCAATAACC-3′; LANA reverse: 5′-CCGTAAGGCACCCTTATCTTT-3′. Specificity of amplification was assessed by analyzing melting curve. KSHV genome copy number was normalized by that of GAPDH and the fold increase of the KSHV genomic DNA copy number was calculated compared to that of uninduced iSLK.219 cells.
Western blot analysis
Western blotting was conducted using NuPAGE SDS-PAGE Gel System (Life Technologies). Cell lysates were prepared in NETN 150 buffer (sodium chloride, 150 mM; EDTA, 2 mM; Tri-HCl, 50 mM; NP-40, 1%) containing protease inhibitor cocktail (cOmplete mini, Roche). Protein separation and Western blotting were performed according to the manufacturer’s instructions69,70.
Flow cytometry
Cells were subjected to flow cytometry analysis with an LSRII (BD Biosciences), and the data were analyzed by FlowJo software. Transformed or primary endothelial cells were trypsinized before staining with specific antibodies to CD119 or CD120a with subsequent washes before being subjected to flow cytometry.
Custom KSHV tiling array
Total RNA was extracted from induced iSLK.219 cultured in the presence/absence of inhibitory cytokines using RNA-Bee (Tel-Test Inc.) and further purified utilizing the RNEASY Mini Kit (QIAGEN) according to the manufacturer’s instructions. Detailed procedures were described elsewhere26,42. Briefly, Cy5 (samples) or Cy3 (reference)-labeled complementary RNA (cRNA) was prepared using the Quick Amp Labeling Kit (Agilent) according to the manufacturer’s protocols. Labeled cRNAs were hybridized onto a custom KSHV tiling microarray (Agilent, custom design identification number: 029238). Array scanning was performed using the GenePix (Molecular Devices), and features were extracted using GenePix Pro software. Heat maps were generated from annotated data using the Java Treeview software.
Statistics
Data represented in this study are shown as means ± SEM of 3 or more independent experiments. The significance of differences in the mean values was evaluated by one-way ANOVA Tukey method. P < 0.01 was considered statistically significant.
Acknowledgements
We thank Dr. Don Ganem for his critical reading of the manuscript. The research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education 92017R1A6A1A03015876 and HI15C3039 through the Korea Health Industry Development Institute (KHIDI) funded by the Korean Ministry of Health and Welfare.
Author Contributions
J.M. conceptualized, performed, and directed this original study. J.M. and M.P. designed the study. J.M., H.C., M.P., S.W.R. and S.K. performed the experiments. J.M. and M.P. analyzed the data. J.M. and M.P. wrote the manuscript.
Data Availability
All data generated or analyzed during this study are included in this published article.
Competing Interests
The authors declare no competing interests.
Footnotes
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Ensoli B, et al. Biology of Kaposi’s sarcoma. Eur J Cancer. 2001;37:1251–1269. doi: 10.1016/S0959-8049(01)00121-6. [DOI] [PubMed] [Google Scholar]
- 2.Nickoloff BJ, Griffiths CE. The spindle-shaped cells in cutaneous Kaposi’s sarcoma. Histologic simulators include factor XIIIa dermal dendrocytes. Am J Pathol. 1989;135:793–800. [PMC free article] [PubMed] [Google Scholar]
- 3.Nickoloff BJ, Griffiths CE. Factor XIIIa-expressing dermal dendrocytes in AIDS-associated cutaneous Kaposi’s sarcomas. Science. 1989;243:1736–1737. doi: 10.1126/science.2564703. [DOI] [PubMed] [Google Scholar]
- 4.Herndier B, Ganem D. The biology of Kaposi’s sarcoma. Cancer Treat Res. 2001;104:89–126. doi: 10.1007/978-1-4615-1601-9_4. [DOI] [PubMed] [Google Scholar]
- 5.Kang S, Myoung J. Primary lymphocyte infection models for KSHV and its putative tumorigenesis mechanisms in B cell lymphomas. J Microbiol. 2017;55:319–329. doi: 10.1007/s12275-017-7075-2. [DOI] [PubMed] [Google Scholar]
- 6.Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest. 2010;120:939–949. doi: 10.1172/JCI40567. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ensoli B, et al. AIDS-Kaposi’s sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science. 1989;243:223–226. doi: 10.1126/science.2643161. [DOI] [PubMed] [Google Scholar]
- 8.Ganem, D. In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis (eds A. Arvin et al.) (2007). [PubMed]
- 9.Ensoli B, Sturzl M. Kaposi’s sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Cytokine Growth Factor Rev. 1998;9:63–83. doi: 10.1016/S1359-6101(97)00037-3. [DOI] [PubMed] [Google Scholar]
- 10.Ensoli B, Sturzl M, Monini P. Reactivation and role of HHV-8 in Kaposi’s sarcoma initiation. Adv Cancer Res. 2001;81:161–200. doi: 10.1016/S0065-230X(01)81005-8. [DOI] [PubMed] [Google Scholar]
- 11.Oxholm A, Oxholm P, Permin H, Bendtzen K. Epidermal tumour necrosis factor alpha and interleukin 6-like activities in AIDS-related Kaposi’s sarcoma. An immunohistological study. APMIS. 1989;97:533–538. doi: 10.1111/j.1699-0463.1989.tb00827.x. [DOI] [PubMed] [Google Scholar]
- 12.Sturzl M, et al. Identification of interleukin-1 and platelet-derived growth factor-B as major mitogens for the spindle cells of Kaposi’s sarcoma: a combined in vitro and in vivo analysis. Oncogene. 1995;10:2007–2016. [PubMed] [Google Scholar]
- 13.Xerri L, et al. Fibroblast growth factor gene expression in AIDS-Kaposi’s sarcoma detected by in situ hybridization. Am J Pathol. 1991;138:9–15. [PMC free article] [PubMed] [Google Scholar]
- 14.Miles SA, et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA. 1990;87:4068–4072. doi: 10.1073/pnas.87.11.4068. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Samaniego F, Markham PD, Gallo RC, Ensoli B. Inflammatory cytokines induce AIDS-Kaposi’s sarcoma-derived spindle cells to produce and release basic fibroblast growth factor and enhance Kaposi’s sarcoma-like lesion formation in nude mice. J Immunol. 1995;154:3582–3592. [PubMed] [Google Scholar]
- 16.Samaniego F, Markham PD, Gendelman R, Gallo RC, Ensoli B. Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi’s sarcoma-like lesions in nude mice. J Immunol. 1997;158:1887–1894. [PubMed] [Google Scholar]
- 17.Samaniego F, et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi’s sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol. 1998;152:1433–1443. [PMC free article] [PubMed] [Google Scholar]
- 18.Sciacca FL, et al. Expression of adhesion molecules, platelet-activating factor, and chemokines by Kaposi’s sarcoma cells. J Immunol. 1994;153:4816–4825. [PubMed] [Google Scholar]
- 19.Nakamura S, et al. Interdigitating cell sarcoma. A morphologic, immunohistologic, and enzyme-histochemical study. Cancer. 1988;61:562–568. doi: 10.1002/1097-0142(19880201)61:3<562::AID-CNCR2820610323>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
- 20.Radka SF, Nakamura S, Sakurada S, Salahuddin SZ. Correlation of oncostatin M secretion by human retrovirus-infected cells with potent growth stimulation of cultured spindle cells from AIDS-Kaposi’s sarcoma. J Immunol. 1993;150:5195–5201. [PubMed] [Google Scholar]
- 21.Roth WK, Werner S, Schirren CG, Hofschneider PH. Depletion of PDGF from serum inhibits growth of AIDS-related and sporadic Kaposi’s sarcoma cells in culture. Oncogene. 1989;4:483–487. [PubMed] [Google Scholar]
- 22.Bais C, et al. G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 1998;391:86–89. doi: 10.1038/34193. [DOI] [PubMed] [Google Scholar]
- 23.Cornali E, et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi’s sarcoma. Am J Pathol. 1996;149:1851–1869. [PMC free article] [PubMed] [Google Scholar]
- 24.Fiorelli V, Gendelman R, Samaniego F, Markham PD, Ensoli B. Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi’s sarcoma spindle cells. J Clin Invest. 1995;95:1723–1734. doi: 10.1172/JCI117849. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Ye F, et al. Reactive oxygen species hydrogen peroxide mediates Kaposi’s sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog. 2011;7:e1002054. doi: 10.1371/journal.ppat.1002054. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Myoung J, Ganem D. Infection of lymphoblastoid cell lines by Kaposi’s sarcoma-associated herpesvirus: critical role of cell-associated virus. J Virol. 2011;85:9767–9777. doi: 10.1128/JVI.05136-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Myoung J, Ganem D. Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J Virol Methods. 2011;174:12–21. doi: 10.1016/j.jviromet.2011.03.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Sturzl M, Gaus D, Dirks WG, Ganem D, Jochmann R. Kaposi’s sarcoma-derived cell line SLK is not of endothelial origin, but is a contaminant from a known renal carcinoma cell line. Int J Cancer. 2013;132:1954–1958. doi: 10.1002/ijc.27849. [DOI] [PubMed] [Google Scholar]
- 29.Chang HH, Ganem D. A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity. Cell Host Microbe. 2013;13:429–440. doi: 10.1016/j.chom.2013.03.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Weninger W, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi’s sarcoma tumor cells. Lab Invest. 1999;79:243–251. [PubMed] [Google Scholar]
- 31.Arias C, et al. KSHV 2.0: a comprehensive annotation of the Kaposi’s sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features. PLoS Pathog. 2014;10:e1003847. doi: 10.1371/journal.ppat.1003847. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Lu M, et al. Dissection of the Kaposi’s sarcoma-associated herpesvirus gene expression program by using the viral DNA replication inhibitor cidofovir. J Virol. 2004;78:13637–13652. doi: 10.1128/JVI.78.24.13637-13652.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Parravicini C, et al. Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases: Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Am J Pathol. 2000;156:743–749. doi: 10.1016/S0002-9440(10)64940-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Dittmer DP. Restricted Kaposi’s sarcoma (KS) herpesvirus transcription in KS lesions from patients on successful antiretroviral therapy. MBio. 2011;2:e00138–00111. doi: 10.1128/mBio.00138-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Hosseinipour MC, et al. Viral profiling identifies multiple subtypes of Kaposi’s sarcoma. MBio. 2014;5:e01633–01614. doi: 10.1128/mBio.01633-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Wakeham K, et al. Trends in Kaposi’s sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi’s sarcoma: a nested case-control study. Int J Cancer. 2015;136:2822–2830. doi: 10.1002/ijc.29329. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Pauk J, et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med. 2000;343:1369–1377. doi: 10.1056/NEJM200011093431904. [DOI] [PubMed] [Google Scholar]
- 38.Koelle DM, et al. Frequent detection of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. J Infect Dis. 1997;176:94–102. doi: 10.1086/514045. [DOI] [PubMed] [Google Scholar]
- 39.Vieira J, Huang ML, Koelle DM, Corey L. Transmissible Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi’s sarcoma. J Virol. 1997;71:7083–7087. doi: 10.1128/jvi.71.9.7083-7087.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Martin JN. Diagnosis and epidemiology of human herpesvirus 8 infection. Semin Hematol. 2003;40:133–142. doi: 10.1053/shem.2003.50013. [DOI] [PubMed] [Google Scholar]
- 41.Minhas V, Wood C. Epidemiology and transmission of Kaposi’s sarcoma-associated herpesvirus. Viruses. 2014;6:4178–4194. doi: 10.3390/v6114178. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Myoung J, Ganem D. Infection of primary human tonsillar lymphoid cells by KSHV reveals frequent but abortive infection of T cells. Virology. 2011;413:1–11. doi: 10.1016/j.virol.2010.12.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Myoung J, Ganem D. Active lytic infection of human primary tonsillar B cells by KSHV and its noncytolytic control by activated CD4+ T cells. J Clin Invest. 2011;121:1130–1140. doi: 10.1172/JCI43755. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Fiorelli V, et al. gamma-Interferon produced by CD8+ T cells infiltrating Kaposi’s sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection? Blood. 1998;91:956–967. [PubMed] [Google Scholar]
- 45.Sirianni MC, et al. gamma-Interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi’s sarcoma patients: correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages. Blood. 1998;91:968–976. [PubMed] [Google Scholar]
- 46.Barillari G, et al. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi’s sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol. 1999;163:1929–1935. [PubMed] [Google Scholar]
- 47.Fiorelli V, et al. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi’s sarcoma pathogenesis. J Immunol. 1999;162:1165–1170. [PubMed] [Google Scholar]
- 48.Monini P, et al. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi’s sarcoma. Blood. 1999;93:4044–4058. [PubMed] [Google Scholar]
- 49.Blackbourn DJ, Fujimura S, Kutzkey T, Levy JA. Induction of human herpesvirus-8 gene expression by recombinant interferon gamma. AIDS. 2000;14:98–99. doi: 10.1097/00002030-200001070-00017. [DOI] [PubMed] [Google Scholar]
- 50.Chang J, Renne R, Dittmer D, Ganem D. Inflammatory cytokines and the reactivation of Kaposi’s sarcoma-associated herpesvirus lytic replication. Virology. 2000;266:17–25. doi: 10.1006/viro.1999.0077. [DOI] [PubMed] [Google Scholar]
- 51.Mercader M, et al. Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am J Pathol. 2000;156:1961–1971. doi: 10.1016/S0002-9440(10)65069-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Pozharskaya VP, Weakland LL, Offermann MK. Inhibition of infectious human herpesvirus 8 production by gamma interferon and alpha interferon in BCBL-1 cells. J Gen Virol. 2004;85:2779–2787. doi: 10.1099/vir.0.80214-0. [DOI] [PubMed] [Google Scholar]
- 53.Boshoff C, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science. 1997;278:290–294. doi: 10.1126/science.278.5336.290. [DOI] [PubMed] [Google Scholar]
- 54.Weck KE, et al. Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. Nat Med. 1997;3:1346–1353. doi: 10.1038/nm1297-1346. [DOI] [PubMed] [Google Scholar]
- 55.Ebrahimi B, Dutia BM, Brownstein DG, Nash AA. Murine gammaherpesvirus-68 infection causes multi-organ fibrosis and alters leukocyte trafficking in interferon-gamma receptor knockout mice. Am J Pathol. 2001;158:2117–2125. doi: 10.1016/S0002-9440(10)64683-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Steed A, Buch T, Waisman A, Virgin HWT. Gamma interferon blocks gammaherpesvirus reactivation from latency in a cell type-specific manner. J Virol. 2007;81:6134–6140. doi: 10.1128/JVI.00108-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Steed AL, et al. Gamma interferon blocks gammaherpesvirus reactivation from latency. J Virol. 2006;80:192–200. doi: 10.1128/JVI.80.1.192-200.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Milligan S, Robinson M, O’Donnell E, Blackbourn DJ. Inflammatory cytokines inhibit Kaposi’s sarcoma-associated herpesvirus lytic gene transcription in in vitro-infected endothelial cells. J Virol. 2004;78:2591–2596. doi: 10.1128/JVI.78.5.2591-2596.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Brown HJ, et al. NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol. 2003;77:8532–8540. doi: 10.1128/JVI.77.15.8532-8540.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med. 2004;199:993–1003. doi: 10.1084/jem.20031467. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 61.Grossmann C, Ganem D. Effects of NFkappaB activation on KSHV latency and lytic reactivation are complex and context-dependent. Virology. 2008;375:94–102. doi: 10.1016/j.virol.2007.12.044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Dupin N, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. Proc Natl Acad Sci USA. 1999;96:4546–4551. doi: 10.1073/pnas.96.8.4546. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Aboulafia D, Miles SA, Saks SR, Mitsuyasu RT. Intravenous recombinant tumor necrosis factor in the treatment of AIDS-related Kaposi’s sarcoma. J Acquir Immune Defic Syndr. 1989;2:54–58. [PubMed] [Google Scholar]
- 64.Ganser A, et al. Treatment of AIDS-related Kaposi’s sarcoma with recombinant gamma-interferon. Onkologie. 1986;9:163–166. doi: 10.1159/000215998. [DOI] [PubMed] [Google Scholar]
- 65.Krigel RL, et al. Therapeutic trial of interferon-gamma in patients with epidemic Kaposi’s sarcoma. J Biol Response Mod. 1985;4:358–364. [PubMed] [Google Scholar]
- 66.Vieira J, O’Hearn P, Kimball L, Chandran B, Corey L. Activation of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J Virol. 2001;75:1378–1386. doi: 10.1128/JVI.75.3.1378-1386.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Lagunoff M, et al. De novo infection and serial transmission of Kaposi’s sarcoma-associated herpesvirus in cultured endothelial cells. J Virol. 2002;76:2440–2448. doi: 10.1128/jvi.76.5.2440-2448.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Eckstein DA, et al. HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity. 2001;15:671–682. doi: 10.1016/S1074-7613(01)00217-5. [DOI] [PubMed] [Google Scholar]
- 69.Cho M, Myoung J. OX40 and 4-1BB downregulate Kaposi’s sarcoma-associated herpesvirus replication in lymphatic endothelial cells, but 4-1BB and not OX40 inhibits viral replication in B-cells. J Gen Virol. 2015;96:3635–3645. doi: 10.1099/jgv.0.000312. [DOI] [PubMed] [Google Scholar]
- 70.Kang S, Myoung J. Host Innate Immunity against Hepatitis E Virus and Viral Evasion Mechanisms. J Microbiol Biotechnol. 2017;27:1727–1735. doi: 10.4014/jmb.1708.08045. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data generated or analyzed during this study are included in this published article.